

1008-3204-1-PB.pdf

by Istyastono_5 Enade

Submission date: 29-Aug-2017 05:19PM (UTC+0700)

Submission ID: 840865258

File name: 1008-3204-1-PB.pdf (364.5K)

Word count: 4835

Character count: 24788

COMPUTER-AIDED DRUG REPURPOSING: A CYCLOOXYGENASE-2 INHIBITOR CELECOXIB AS A LIGAND FOR ESTROGEN RECEPTOR ALPHA

Enade Perdana Istyastono^{1,4,*}, Florentinus Dika Octa Riswanto², and Sri Hartati Yuliani³

¹Division of Drug Design and Discovery, Faculty of Pharmacy, Sanata Dharma University
Paingan, Maguwohardjo, Depok, Yogyakarta 55282, Indonesia

²Division of Food and Drug Safety, Quality and Efficacy, Faculty of Pharmacy, Sanata Dharma University
Paingan, Maguwohardjo, Depok, Yogyakarta 55282, Indonesia

³Division of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Sanata Dharma University
Paingan, Maguwohardjo, Depok, Yogyakarta 55282, Indonesia

⁴Center for Environmental Studies Sanata Dharma University (CESSDU)
Soropadan, Condongcatur, Depok, Yogyakarta 55283, Indonesia

Received April 17, 2015; Accepted August 6, 2015

ABSTRACT

A cyclooxygenase-2 (COX-2) inhibitor celecoxib has been previously reported to have cytotoxic activities towards gastric, prostate, ovarian, colon and breast cancer cell lines. This article reports that the cytotoxic activities of celecoxib could be resulted from its activity as a potent ligand for estrogen receptor alpha (ER α). Aided by molecular docking simulations, an in silico test to examine whether celecoxib is a ligand for estrogen receptor alpha (ER α) was performed followed by in vitro test employing cytotoxic assay using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) method. The compound was extracted from Celebrex®. Measured by using UV spectrophotometric method at 255.5 nm, it was identified that the content of celecoxib was 102.15 mg/271.48 mg capsule content. The in silico test indicated that celecoxib is a potent ligand for ER α . This finding was confirmed experimentally by an in vitro test that celecoxib has a comparable activity as an ER α ligand to tamoxifen, a drug of choice for breast cancer treatment.

Keywords: cyclooxygenase-2; estrogen receptor alpha; molecular docking; celecoxib

ABSTRAK

Obat anti-inflamasi celecoxib, sebuah inhibitor siklooksigenase (COX-2), diketahui memiliki aktivitas sitotoksik pada sel kanker saluran pencernaan, prostat, indung telur dan payudara. Dalam artikel ini disampaikan bahwa aktivitas sitotoksik tersebut diduga berkaitan dengan aktivitas senyawa tersebut sebagai ligan pada reseptor estrogen alfa (ER α). Bertulangpunggungan simulasi penambatan molekuler, uji in silico untuk mengevaluasi aktivitas celecoxib sebagai ligan pada ER α yang diverifikasi secara in vitro melalui uji sitotoksik dengan metode 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT). Senyawa uji celecoxib diekstrak dari kapsul Celebrex® yang ditetapkan kadarnya dengan metode spektrofotometri UV pada panjang gelombang 255,5 nm. Diketahui bahwa kadar celecoxib dalam kapsul adalah 102,15 mg tiap 271,48 mg isi kapsul. Hasil uji in silico mengindikasikan bahwa celecoxib merupakan ligan poten pada ER α . Hasil ini dikonfirmasi secara in vitro bahwa celecoxib memiliki aktivitas sebagai ligan pada ER α dengan potensi serupa dengan tamoxifen, obat pilihan untuk kanker payudara.

Kata Kunci: siklooksigenase-2; reseptor estrogen alfa; penambatan molekuler; celecoxib

INTRODUCTION

Celecoxib (Fig. 1A) is widely marketed as a selective cyclooxygenase-2 (COX-2) anti-inflammatory drug and has proven to be a blockbuster drug [1-2]. Interestingly, it shows some indications of its role in the cancer pathophysiology, especially in the apoptosis

pathways [3]. Celecoxib was reported to play an important role in inhibiting the proliferation of the NPC cell lines [3-4], modulating the expression of Bcl-2 family members and mitochondria-mediated apoptosis [3,5], regulating Survivin, Mcl-1, Bcl-2 and Cyclin D1 [3-5], and inducing apoptosis and cell-cycle arrest at the G(0)/G(1) checkpoint [3-4]. As a COX-2 inhibitor [2,6-7],

* Corresponding author.
Email address : enade@usd.ac.id




Fig 1. Structures of celecoxib (A) and tamoxifen (B)

celecoxib shows anticancer properties in some cancer cell lines including colon cancer [8] and prostate cancer [9]. However, this drug suppresses also another COX-2 independent molecular pathway in prostate cancer [9]. Celecoxib is suggested also to have activities against breast cancer since breast is a tissue involved in COX-2 up regulation [10]. Crosstalk of COX-2 with estrogen receptor alpha (ER α) pathway was suggested to play an important role in the activities of celecoxib in the breast cancer pathophysiology [11].

An ER α antagonist tamoxifen (Fig. 1B) is the standard adjuvant for postmenopausal women with hormone-receptor-positive early breast cancer [12]. Notably, tamoxifen is a prodrug since it is metabolized to some active metabolites (e.g., 4-hydroxytamoxifen and *N*-desmethyl-4-hydroxy-tamoxifen) in the liver [13]. The affinity of the metabolites to ER α is 30-100 fold higher compared to tamoxifen in its original form [13]. In a recent prospective structure-based virtual screening (SBVS) campaign on the ZINC drug database (ZDD) [14] to discover ligands for ER α [15], celecoxib (ZINC02570895 [14]) together with 67 other drugs were identified as potent ligands for ER α [15]. It is therefore of a considerable and timely interest to verify whether celecoxib is a potent ligand for ER α .

In this article, exhaustive SBVS campaigns followed by *in vitro* tests to verify whether celecoxib a potent ligand for ER α are presented. The research aimed to employ computer-aided drug repurposing strategy [16] to verify the activity of celecoxib as a potent ligand for ER α . The SBVS protocol used to perform *in silico* tests was initially constructed and retrospectively validated by Anita et al. [17] to identify ER α antagonists [18]. By incorporating PyPLIF [19], subsequently the protocol was re-validated and reported that the protocol employing PyPLIF has a significantly better quality [19-21]. The *in silico* screenings followed by *in vitro* tests employing tamoxifen as the reference compound has confirmed that celecoxib is a potent ligand for ER α .

EXPERIMENTAL SECTION

Materials

Celecoxib in three dimensional (3D) mode in the form of a mol2 file was obtained from the ZINC database

[14]. The ZINC code of celecoxib was ZINC02570895 [14,22]. Configuration files to perform *in silico* tests to identify celecoxib as ER α ligand by using PLANTS docking software were obtained from Anita et al. [17]: (i) The virtual target *protein.mol2*, (ii) the conserved water molecule *water.mol2*, and (iii) the configuration files to run PLANTS docking software *plants.config*. Configuration files to perform protein-ligand interaction fingerprints (PLIF) identification using PyPLIF were obtained from Radifar et al. [19]: (i) The configuration file to run PyPLIF *config.txt*, (ii) the virtual reference structure *OHT.mol2*, and (iii) the virtual binding pocket residues *PLANTSActiveSiteResidues.mol2*.

Celecoxib standard was purchased from Sigma-Aldrich. Sample was prepared from Celebrex® (Pfizer) contain 100 mg celecoxib dissolved in dimethyl sulfoxide (DMSO) Merck®. MCF-7 breast cancer cell line was derived from Parasitology Laboratory, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia. Dulbecco's Modified Eagle Medium (DMEM) (Gibco) as culture medium was purchased from Gibco. Cytotoxic assay was performed using 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) (Sigma). Sodium dodecyl sulphate as stopper reagent was obtained from Merck. Tamoxifen as the reference compound in DMEM was provided by Setiawati et al. [23]. This research used US BIO ER α primary antibody [23]. All culture plates used in this study were Iwaki and all tips were purchased from Biologix.

Instrumentation and Computation

Instrumentation used in this study was Shimadzu UV-1800 spectrophotometer, cuvette Hellma, Retsch tipe T460 No V935922013 EY ultrasonicator, Scaltec SBC 22 (max 60/210 g, min 0.001 g, d = 0.01/0.1 mg) analytical balance, and Socorex micropipette. Computational medicinal chemistry applications used in this research were: PLANTS docking software version 1.2 (PLANTS1.2) [24, 25] to perform molecular docking simulations, R computational statistics software version 3.1.2 to perform statistical tests [26] and PyPLIF [19,27] to identify PLIF. All calculations and computational simulations were performed on a Linux (Ubuntu 12.04 LTS) machine with Intel® Xeon® CPU E31220 (@ 3.10 GHz) as the processors and 8.00 GB of RAM.

Procedure

Virtual screening on celecoxib as ligand for ER α

The previously published procedure by Anita et al. [17] was employed to dock celecoxib to ER α binding pocket three times [17,20]. The docked poses resulted

in the molecular docking simulations were subsequently subjected to PyPLIF to identify their PLIF [19]. Only docking poses whose bitstring of 103 is 1 were selected [19]. From the remaining poses, the best pose of each run was selected as the pose with the best Tanimoto coefficient similarity on the PLIF compared to the PLIF of the co-crystal ligand 4-hydroxytamoxifen (Tc-PLIF) [19,24] of all three independent runs. This procedure was performed 1000 times independently. The Tc-PLIF values of all selected poses from those 1000 independent run were subjected to a relevant statistical test to examine whether the Tc-PLIF values were statistically higher or equal to the Tc-PLIF standard 0.720 [19] in level of confidence of 95% [26].

Determination of celecoxib in Celebrex®

Standard solution preparation: A celecoxib stock solution was obtained by weighing 0.1520 mg of celecoxib standard accurately into a 1 mL vial, dissolved, and diluted to volume with DMSO. The intermediate solution was obtained by transferring 0.8 mL of celecoxib stock solution into a 5 mL volumetric flask, dissolved, and diluted to volume with DMSO. The calibration standard solution of celecoxib was obtained by transferring 200, 300, 400, 500, 600, and 700 μ L of intermediate solution of celecoxib into 5 mL volumetric flask and dilute to volume with DMSO. **Selection of wavelength:** The maximum absorption wavelength of celecoxib was determined at the beginning of the study by scanning the standard solution at 200-400 nm. The maximum absorption wavelength was determined and used for the next determination. **Sample preparation:** Twenty capsules of Celebrex® were accurately weighed. An equivalent amount of 50 mg of the drug was taken and dissolved in DMSO and filtered; volume was made up to 25 mL. The sample solution was obtained by transferring 10 μ L of stock sample solution into a 10 mL volumetric flask, dissolved, and diluted to volume with DMSO.

MTT cytotoxic assay and immunocyto staining of ER α

MCF-7 cells were cultured until confluent in DMEM then 5×10^3 cells were seeded into 96-well microplate and incubated in 37 °C and 5% CO₂ for 24 h. Celecoxib as stock solution was prepared by dissolving the content of Celebrex® capsules in DMSO. Then, DMEM was removed and a series concentration of celecoxib in DMEM (5.00, 10.00, 25.00, 50.00, 75.00, and 100.00 μ M) were added into 96-well plate 100 μ L each and incubated in the same as previous condition for 24 h. Each concentration was assayed triplo (n = 3). In the end of incubation time, DMEM was removed from cells and 100 μ L DMEM containing 5 mg/mL MTT was added into well plate. The plate was incubated for 4 h,




Fig 2. The histogram of all Tc-PLIF values resulted in docking using PLANTS1.2 followed by re-scoring using PyPLIF of celecoxib to ER α

then 100 μ L of 10% SDS was added to each well to dissolve crystal formazan. The 96-well microplate was incubated for 24 h in dark room. Formazan crystals were measured by ELISA reader using 595 nm wavelengths. The half-maximal inhibitory concentration (IC₅₀) value was calculated using four parameters logistic regression by employing R computational statistics software version 3.1.2 [26,28]. Similar procedures were subjected to a series concentration of tamoxifen in DMEM (5.00, 10.00, 25.00, 40.00, 50.00, and 100.00 μ M) as the reference compound [23]. By employing the method of ER α immunocyto staining published previously [23], the expression of ER α after adding celecoxib 30 μ M was examined compared to the expression of ER α after adding tamoxifen 24 μ M.

RESULT AND DISCUSSION

This research aimed to examine whether a widely used and well-known anti-inflammatory compound celecoxib is also a potent ligand for ER α . The identification of celecoxib as a potential ligand for ER α was performed by employing computational chemistry method, which was subsequently confirmed by *in vitro* tests. This approach can serve as an example of computer-aided drug repurposing in discovery of novel ligands for ER α .

The *in silico* tests resulted in Tc-PLIF values of 0.654 to 0.792 with mean (standard deviation) value of 0.728 (0.024). The histogram of all 1000 Tc-PLIF values (Fig. 2) indicates that the data is not normally distributed, which was confirmed by performing Shapiro-Wilk test (p-value < 0.05). Since the data was not normally distributed, one sample Wilcoxon test was

performed instead of one sample t-test to examine whether the Tc-PLIF values are equal or higher than the reference Tc-PLIF value (0.720) [19] (H_0) or the Tc-PLIF values are less than the reference Tc-PLIF value (H_1). The Wilcoxon test resulted in p-value of 1. This means that at the 95% level of confidences, the Tc-PLIF values are equal or better than 0.720 statistically. This result indicated that celecoxib is a potent ligand for ER α [1,3,17,19,21]. *In vitro* tests to confirm these *in silico* results were therefore required [17,19,29-36].

In this study, *in vitro* tests serve as the verification of the *in silico* test results [30-34,37-39]. On the other hand, *in silico* approaches could assist in the explanation of *in vitro* tests [35,40-47]. Very recently, the virtual screening protocol mainly referred in this study [17,19] was retrospectively re-validated [20] using the newest benchmarking dataset provided by Mysinger et al. [36]. The retrospective re-validation resulted in a better parameter that increased the confidence to further examine celecoxib as a ligand for ER α [20]. However, the cutoff value used in this study (Tc-PLIF value of 0.720) was the one suggested by Radifar et al. [19] since the retrospective validation showed a better parameter as a virtual screening protocol to identify potent ER α in an early enrichment (at 1% false positives) compared to the retrospective validation by Setiawati et al. [20]. Unfortunately, the quality of both virtual screening protocols to identify ER α ligands globally (at 100% false positives) could not be compared since Radifar et al. [19] did not provide the value. In fact, combined scoring functions using both scoring functions from PLANTS1.2 (ChemPLP) [24] and PLIF-based scoring functions [7,19,21,48] are highly recommended recently [32,49,50]. On the other hand, both benchmarking datasets [18,36] requires potent ligands with IC₅₀ value ≤ 1 μ M, which decreases the predictive ability of the VS protocols to identify moderate ligands (IC₅₀ values of 1 mM to 1 μ M) [17,19-21,23].

Since the approach presented in this article was aimed to employ computer-aided drug repurposing strategies, Celebrex® containing 100 mg celecoxib was

employed instead of pure celecoxib. By using UV spectrophotometric method, the amount of celecoxib in Celebrex® was determined [51]. Quantification of drug substance using spectrophotometer was carried out by preparing solution in transparent solvent and measuring its absorbance at suitable wavelength [51]. Different with Revathi et al. [51] which used chloroform as solvent with detection wavelength at 255 nm, the standard solutions of celecoxib (1.46, 1.95, and 2.43 μ g/mL) in this study were dissolved in DMSO. The solutions were scanned at the wavelength region of 210-400 nm since the nature of the solvent could alter the position of the spectral peaks [52-53]. The maximum absorption wavelength of 255.5 nm was found. Six points calibration curve were subsequently obtained in a concentration range from 0.97-3.40 μ g/mL for celecoxib. The response of the drug was found to be linear in the investigation concentration range and the linear regression equation was $y = 0.047x + 0.127$ with correlation coefficient 0.9929, which was considered as statistically acceptable since the experimental value of the coefficient of correlation (r) was larger than the

Fig 3. Dose response curves for celecoxib and tamoxifen effect on MCF-7 cell viability

Table 1. Effect of celecoxib and tamoxifen on MCF-7 cell viability after 24 h incubation

Celecoxib		Tamoxifen	
Concentration (μ M)	Percentage of MCF-7 viability (mean \pm SEM)	Concentration (μ M)	Percentage of MCF-7 viability (mean \pm SEM)
100	5.93 \pm 0.23	100	15.67 \pm 4.00
75	44.54 \pm 4.33	50	19.90 \pm 3.75
50	77.58 \pm 4.61	40	53.46 \pm 1.77
25	102.28 \pm 2.45	25	84.33 \pm 2.68
10	88.98 \pm 3.31	10	85.38 \pm 0.58
5	97.87 \pm 4.47	5	86.83 \pm 2.31
IC ₅₀ value of celecoxib = 94.06 \pm 14.30 μ M		IC ₅₀ value of tamoxifen = 40.78 \pm 0.48 μ M	
R ² of the logistic regression model = 0.983 [†]		R ² of the logistic regression model = 0.999 [†]	

[†] The R² value of both models show that the models are acceptable to calculate the IC₅₀ value since the values are larger than the tabulated ones for the given number of determinations ($n = 6$; R² = 0.658) at the 95% level of confidences [44,54]

Fig 4. The ER α expression using immunocytochemistry method observed under light microscope using 400x magnification [23]. (A) Untreated cells; (B) Untreated cells without antibody; (C) Trated with celecoxib (30 μ M); and (D) Treated with tamoxifen (24 μ M). Symbol "■" points the expressed ER α [23]

tabulated one for the given number of determinations ($n = 6$; $r = 0.811$) at the 95% level of confidences [54].

Celecoxib concentrations in six determinations were 36.93, 37.32, 38.62, 37.58, 38.2, and 37.09% (w/w), respectively. The mean (standard deviation) of the concentrations was 37.67 (0.67)% (w/w) or 102.15 mg celecoxib in 271.48 mg capsule content. Since the percent relative standard deviation (RSD) obtained on the six determinations of celecoxib was 1.78%, the precision was considered as acceptable (RSD < 7.3%) [52,55].

After determining the celecoxib content in the Celebrex® capsules sample, the cytotoxic activity of celecoxib against MCF-7 cell line was subsequently evaluated. The cell line is one of the established cell line to examine the activity of compounds as ligands for ER α [20,23,56-57]. Celecoxib treatment on MCF-7 cells changed both of cell viability and morphology. The compound showed strong cytotoxic activity towards MCF-7 cell line with IC₅₀ (standard error of measurement (SEM)) value of 94.06 (14.30) μ M, while tamoxifen as the reference compound showed IC₅₀ (SEM) value of 40.78 (0.48) μ M (Table 1; Fig. 3). Since the Shapiro-Wilk normality test show that the data were normally distributed but the variance were not homogen, Welch two sample t-test were performed to examine whether the IC₅₀ values of celecoxib were different to the IC₅₀ values of tamoxifen (H_1) or not (H_0). The Welch two sample t-test showed that at the 95% level of confidences the IC₅₀ values of celecoxib were statistically not different to the IC₅₀ values of tamoxifen (p-value of 0.065). Moreover, the IC₅₀ value of celecoxib is in the same micromolar range with the IC₅₀ value of tamoxifen. These results are inline with the results from the *in silico* tests that celecoxib is a potent ligand for ER α . Notably, the immunocytochemistry assay results (Fig. 4) supported these findings by showing decrease of ER α expression in both of celecoxib and tamoxifen treatment.

The activity of celecoxib in the breast cancer pathophysiology was suggested as the results from tight

crosstalk of COX-2 with ER α pathway [11]. Interestingly, our findings presented in this article show that celecoxib plays an important role in ER α pathway, not only because it is a potent COX-2 inhibitor but also celecoxib is a potent ligand for ER α . Since these results emerged from computer-aided drug repurposing strategy using molecular docking simulations, the docking pose of celecoxib in the ER α binding pocket could provide insight to further design its analogs or derivatives with better activity towards ER α [2,20,23,50].

CONCLUSION

Aided by computational chemistry tools, a potent anti-inflammatory drug celecoxib was identified as a potent ligand for ER α . *In vitro* tests using MTT method subsequently confirmed that celecoxib is a ligand for ER α with IC₅₀ (SEM) value of 94.06 (14.30) μ M. It is comparable with the IC₅₀ value of a drug of choice for breast cancer tamoxifen.

ACKNOWLEDGEMENT

We thank Agustina Setiawati for her technical assistances with the *in vitro* assay. This research was financially supported by Indonesian Directorate General of Higher Education (Competitive Research Block Grant No. 1320/K5/KM/2014).

REFERENCES

1. Sadée, W., and Bohn, L., 2006, *Mol. Intervention*, 6 (4), 196–198.
2. Penning, T.D., Talley, J.J., Bertenshaw, S.R., Carter, J.S., Collins, P.W., Docter, S., Graneto, M.J., Lee, L.F., Malecha, J.W., Miyashiro, J.M., Rogers, R.S., Rogier, D.J., Yu, S.S., Anderson, G.D., Burton, E.G., Cogburn, J.N., Gregory, S.A., Koboldt, C.M., Perkins, W.E., Seibert, K.,

- Veenhuizen, A.W., Zhang, Y.Y., and Isakson, P.C., 1997, *J. Med. Chem.*, 40 (9), 1347–1365.
3. Jendrossek, V., 2013, *Cancer Lett.*, 332 (2), 313–324.
 4. Liu, D., Hu, G., Long, G., Qiu, H., Mei, Q., and Hu, G., 2012, *Acta Pharmacol. Sin.*, 33 (5), 682–690.
 5. Winfield, L.L., and Payton-Stewart, F., 2012, *Future Med. Chem.*, 4 (3), 361–383.
 6. Rimón, G., Sidhu, R.S., Lauver, D.A., Lee, J.Y., Sharma, N.P., Yuan, C., Frieler, R.A., Trievel, R.C., Lucchesi, B.R., and Smith, W.L., 2010, *Proc. Natl. Acad. Sci. U.S.A.*, 107 (1), 28–33.
 7. Chakraborti, A.K., Garg, S.K., Kumar, R., Motiwala, H.F., and Jadhavar, P.S., 2010, *Curr. Med. Chem.*, 17 (15), 1563–1593.
 8. Williams, C.S., Watson, A.J.M., and Sheng, H., 2000, *Cancer Res.*, 60 (21), 6045–6051.
 9. Patel, M.I., Subbaramaiah, K., Du, B., Chang, M., Yang, P., Newman, R.A., Cardo, C.C., Thaler, H.T., and Dannenberg, A.J., 2005, *Clin. Cancer Res.*, 11 (5), 1999–2007.
 10. Turini, M.E., and DuBois, R.N., 2002, *Annu. Rev. Med.*, 53, 35–57.
 11. Wang, Y.X., Gao, J.X., Wang, X.Y., Zhang, L., and Liu, C.M., 2012, *Tumor Biol.*, 33 (4), 957–966.
 12. Mouridsen, H., Giobbie-Hurder, A., Goldhirsch, A., Thürlimann, B., Paridaens, R., Smith, I., Mauriac, L., Forbes, J.F., Price, K.N., Regan, M.M., Gelber, R.D., and Coates, A.S., 2009, *N. Engl. J. Med.*, 361 (8), 766–776.
 13. Desta, Z., Ward, B.A., Soukhova, N.V., and Flockhart, D.A., 2004, *J. Pharmacol. Exp. Ther.*, 310 (3), 1062–1075.
 14. Irwin, J.J., Sterling, T., Mysinger, M.M., Bolstad, E.S., and Coleman, R.G., 2012, *J. Chem. Inf. Model.*, 52 (7), 1757–1768.
 15. Istyastono, E.P., 2013, *Virtual Screening on ZINC Drug Database to Discover Novel Antagonists for Estrogen Receptor α* , Sanata Dharma University Research Grant Final Report, Universitas Sanata Dharma, Yogyakarta.
 16. Bisson, W.H., Cheltsov, A.V., Bruey-Sedano, N., Lin, B., Chen, J., Goldberger, N., May, L.T., Christopoulos, A., Dalton, J.T., Sexton, P.M., Zhang, X., and Abagyan, R., 2007, *Proc. Natl. Acad. Sci. U.S.A.*, 104 (29), 11927–11932.
 17. Anita, Y., Radifar, M., Kardono, L., Hanafi, M., and Istyastono, E.P., 2012, *Bioinformation*, 8 (19), 901–906.
 18. Huang, N., Shoichet, B.K., and Irwin, J.J., 2006, *J. Med. Chem.*, 49 (23), 6789–6801.
 19. Radifar, M., Yuniarti, N., and Istyastono, E.P., 2013, *Bioinformation*, 9 (6), 325–328.
 20. Setiawati, A., Riswanto, F.D.O., Yuliani, S.H., and Istyastono, E.P., 2014, *Indones. J. Chem.*, 14 (2), 103–108.
 21. Radifar, M., Yuniarti, N., and Istyastono, E.P., 2013, *Indones. J. Chem.*, 13 (3), 283–286.
 22. Irwin, J.J., and Shoichet, B.K., 2005, *J. Chem. Inf. Model.*, 45 (1), 177–182.
 23. Setiawati, A., Riswanto, F.O.D., Yuliani, S.H., and Istyastono, E.P., 2014, *Indonesian J. Pharm.*, 25 (3), 119–124.
 24. Korb, O., Stützle, T., and Exner, T.E., 2009, *J. Chem. Inf. Model.*, 49 (1), 84–96.
 25. Korb, O., Stützle, T., and Exner, T.E., 2007, *Proc. IEEE Swarm Intell. Symp.*, 1 (2), 115–134.
 26. R Development Core Team, 2008, *R: A Language and Environment for Statistical Computing*, Vienna. <http://www.r-project.org>.
 27. Salentin, S., Haupt, V.J., Daminelli, S., and Schroeder, M., 2014, *Prog. Biophys. Mol. Biol.*, 116 (2-3), 174–186.
 28. Kreidenweiss, A., Kremsner, P.G., and Mordmüller, B., 2008, *Malar. J.*, 7 (187), 1–8.
 29. Appiah-Opong, R., Commandeur, J.N.M., van Vugt-Lussenburg, B., and Vermeulen, N.P.E., 2007, *Toxicology*, 235 (1-2), 83–91.
 30. Istyastono, E.P., de Graaf, C., de Esch, I.J.P., and Leurs, R., 2011, *Curr. Top. Med. Chem.*, 11 (6), 661–679.
 31. Istyastono, E.P., Nijmeijer, S., Lim, H.D., van de Stolpe, A., Roumen, L., Kooistra, A.J., Vischer, H.F., de Esch, I.J.P., Leurs, R., and de Graaf, C., 2011, *J. Med. Chem.*, 54 (23), 8136–8147.
 32. de Graaf, C., Kooistra, A.J., Vischer, H.F., Katritch, V., Kuijter, M., Shiroishi, M., Iwata, S., Shimamura, T., Stevens, R.C., de Esch, I.J.P., Leurs, R., 2011, *J. Med. Chem.*, 54 (23), 8195–8206.
 33. Sirici, F., Istyastono, E.P., Vischer, H.F., Kooistra, A.J., Nijmeijer, S., Kuijter, M., Wijtmans, M., Mannhold, R., Leurs, R., de Esch, I.J.P., and de Graaf, C., 2012, *J. Chem. Inf. Model.*, 52 (12), 3308–3324.
 34. Kufareva, I., Katritch, V., Stevens, R.C., and Abagyan, R., 2014, *Structure*, 22 (8), 1120–1139.
 35. Schultes, S., Nijmeijer, S., Engelhardt, H., Kooistra, A.J., Vischer, H.F., de Esch, I.J.P., Haaksma, E.E.J., Leurs, R., and de Graaf, C., 2013, *Med. Chem. Commun.*, 4 (1), 193–204.
 36. Mysinger, M.M., Carchia, M., Irwin, J.J., and Shoichet, B.K., 2012, *J. Med. Chem.*, 55 (14), 6582–6594.
 37. Katritch, V., Jaakola, V., Lane, J.R., Lin, J., Ijzerman, A.P., Yeager, M., Kufareva, I., Stevens, R.C., and Abagyan, R., 2010, *J. Med. Chem.*, 53 (4), 1799–1809.

38. Kolb, P., Rosenbaum, D.M., Irwin, J.J., Fung, J.J., Kobilka, B.K., and Shoichet, B.K., 2009, *Proc. Natl. Acad. Sci. U.S.A.*, 106 (16), 6843–6848.
39. Carlsson, J., Coleman, R.G., Setola, V., Irwin, J.J., Fan, H., Schlessinger, A., Sali, A., Roth, B.L., and Shoichet, B.K., 2011, *Nat. Chem. Biol.*, 7 (11), 769–778.
40. Lim, H.D., Istyastono, E.P., van de Stolpe, A., Romeo, G., Gobbi, S., Schepers, M., Lahaye, R., Menge, W.M.B.P., Zuiderveld, O.P., Jongejan, A., Smits, R.A., Bakker, R.A., Haaksma, E.E.J., Leurs, R., and de Esch, I.J.P., 2009, *Bioorg. Med. Chem.*, 17 (11), 3987–3994.
41. Strasser, A., 2009, *Expert Opin. Drug Discovery*, 4 (10), 1061–1075.
42. Smits, R.A., Adami, M., Istyastono, E.P., Zuiderveld, O.P., van Dam, C.M.E., de Kanter, F.J.J., Jongejan, A., Coruzzi, G., Leurs, R., and de Esch, I.J.P., 2010, *J. Med. Chem.*, 53 (6), 2390–2400.
43. Xiang, Y., Hou, Z., and Zhang, Z., 2012, *Chem. Biol. Drug Des.*, 79 (5), 760–770.
44. Appiah-Opong, R., Commandeur, J.N.M., Istyastono, E.P., Bogaards, J.J., and Vermeulen, N.P.E., 2009, *Xenobiotica*, 39 (4), 302–311.
45. Schultes, S., Engelhardt, H., Roumen, L., Zuiderveld, O.P., Haaksma, E.E.J., de Esch, I.J.P., Leurs, R., and de Graaf, C., 2013, *ChemMedChem*, 8 (1), 49–53.
46. Engelhardt, H., Schultes, S., de Graaf, C., Nijmeijer, S., Vischer, H.F., Zuiderveld, O.P., Dobler, J., Stachurski, K., Mayer, M., Arnhof, H., Scharn, D., Haaksma, E.E.J., de Esch, I.J.P., and Leurs, R., 2013, *J. Med. Chem.*, 56 (11), 4264–4276.
47. Lim, H.D., de Graaf, C., Jiang, W., Sadek, P., McGovern, P.M., Istyastono, E.P., Bakker, R. A, de Esch, I.J.P., Thurmond, R.L., and Leurs, R., 2010, *Mol. Pharmacol.*, 77 (5), 734–743.
48. Marcou, G., and Rognan, D., 2007, *J. Chem. Inf. Model.*, 47 (1), 195–207.
49. Schultes, S., Kooistra, A., Vischer, H., Nijmeijer, S., Haaksma, E., Leurs, R., de Esch, I., and de Graaf, C., 2015, *J. Chem. Inf. Model.*, 55 (5), 1030–1044.
50. Istyastono, E.P., Kooistra, A.J., Vischer, H., Kuijjer, M., Roumen, L., Nijmeijer, S., Smits, R., de Esch, I., Leurs, R., and de Graaf, C., 2015, *Med. Chem. Commun.*, 6, 1003–1017.
51. Revathi, R., Perumal, R.V., Sudharshini, S., Ansar, A.M., Thilagalakshmi, A., and Dinesh, A.P., 2011, *Int. J. Pharm. Sci. Lett.*, 1 (2), 49–50.
52. Riswanto, F.O.D., Lukitaningsih, R.R.E., and Martono, S., 2015, *Indones. J. Chem.*, 15 (1), 9–15.
53. Kealey, D., and Haines, P.J., 2002, *Instant Notes Analytical Chemistry*, BIOS Scientific Publishers Ltd., Oxford, 225–226.
54. Ermer, J., and Miller, J.H., 2005, *Method Validation in Pharmaceutical Analysis: A Guide to Best Practice*, Wiley-VCH Verlag GmbH & Co., Weinheim, 87–90.
55. González, A.G., and Herrador, M.A., 2007, *TrAC, Trends Anal. Chem.*, 26 (3), 227–238.
56. Brooks, S.C., Locke, E.R., and Soule, H.D., 1973, *J. Biol. Chem.*, 248 (17), 6251–6253.
57. Vidhya, N., and Devaraj, S.N., 2011, *Indian J. Exp. Biol.*, 49 (11), 871–878.

ORIGINALITY REPORT

0%

SIMILARITY INDEX

0%

INTERNET SOURCES

0%

PUBLICATIONS

0%

STUDENT PAPERS

PRIMARY SOURCES

Exclude quotes On

Exclude bibliography On

Exclude matches < 25%